These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 17971823)

  • 1. Mass spectrometry and peptide-based vaccine development.
    Ovsyannikova IG; Johnson KL; Bergen HR; Poland GA
    Clin Pharmacol Ther; 2007 Dec; 82(6):644-52. PubMed ID: 17971823
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of HLA class II H5N1 hemagglutinin epitopes following subvirion influenza A (H5N1) vaccination.
    Zinckgraf JW; Sposato M; Zielinski V; Powell D; Treanor JJ; von Hofe E
    Vaccine; 2009 Aug; 27(39):5393-401. PubMed ID: 19596415
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Class II HLA-peptide binding prediction using structural principles.
    Mohanapriya A; Lulu S; Kayathri R; Kangueane P
    Hum Immunol; 2009 Mar; 70(3):159-69. PubMed ID: 19187794
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro human CD4+ T cell response to the vaccinia protective antigens B5R and A33R.
    Sirven P; Castelli FA; Probst A; Szely N; Maillere B
    Mol Immunol; 2009 Apr; 46(7):1481-7. PubMed ID: 19193441
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design and development of synthetic peptide vaccines: past, present and future.
    Bijker MS; Melief CJ; Offringa R; van der Burg SH
    Expert Rev Vaccines; 2007 Aug; 6(4):591-603. PubMed ID: 17669012
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antigenic properties of HCMV peptides displayed by filamentous bacteriophages vs. synthetic peptides.
    Ulivieri C; Citro A; Ivaldi F; Mascolo D; Ghittoni R; Fanigliulo D; Manca F; Baldari CT; Li Pira G; Del Pozzo G
    Immunol Lett; 2008 Aug; 119(1-2):62-70. PubMed ID: 18538862
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunologic and clinical outcomes of a randomized phase II trial of two multipeptide vaccines for melanoma in the adjuvant setting.
    Slingluff CL; Petroni GR; Chianese-Bullock KA; Smolkin ME; Hibbitts S; Murphy C; Johansen N; Grosh WW; Yamshchikov GV; Neese PY; Patterson JW; Fink R; Rehm PK
    Clin Cancer Res; 2007 Nov; 13(21):6386-95. PubMed ID: 17975151
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of class II HLA-DRB1*03-bound measles virus peptides by 2D-liquid chromatography tandem mass spectrometry.
    Johnson KL; Ovsyannikova IG; Poland GA; Muddiman DC
    J Proteome Res; 2005; 4(6):2243-9. PubMed ID: 16335972
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine.
    Welters MJ; Kenter GG; Piersma SJ; Vloon AP; Löwik MJ; Berends-van der Meer DM; Drijfhout JW; Valentijn AR; Wafelman AR; Oostendorp J; Fleuren GJ; Offringa R; Melief CJ; van der Burg SH
    Clin Cancer Res; 2008 Jan; 14(1):178-87. PubMed ID: 18172269
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Contributions of mass spectrometry to structural immunology.
    Downard KM
    J Mass Spectrom; 2000 Apr; 35(4):493-503. PubMed ID: 10797646
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of HLA-DRB1-bound self-peptides following measles virus infection.
    Ovsyannikova IG; Johnson KL; Naylor S; Poland GA
    J Immunol Methods; 2005 Feb; 297(1-2):153-67. PubMed ID: 15777939
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of HLA-DR-restricted T-cell epitopes derived from human proteinase 3.
    Piesche M; Hildebrandt Y; Chapuy B; Wulf GG; Trümper L; Schroers R
    Vaccine; 2009 Jul; 27(34):4718-23. PubMed ID: 19446593
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Purification and HPLC-MS analysis of a naturally processed HCMV-derived peptide isolated from the HEK-293T/HLA-E+/Ul40+ cell transfectants and presented at the cell surface in the context of HLA-E.
    Millo E; Pietra G; Armirotti A; Vacca P; Mingari MC; Moretta L; Damonte G
    J Immunol Methods; 2007 Apr; 322(1-2):128-36. PubMed ID: 17331531
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mining the Leishmania genome for novel antigens and vaccine candidates.
    Herrera-Najera C; Piña-Aguilar R; Xacur-Garcia F; Ramirez-Sierra MJ; Dumonteil E
    Proteomics; 2009 Mar; 9(5):1293-301. PubMed ID: 19206109
    [TBL] [Abstract][Full Text] [Related]  

  • 15. T-Cell epitope discovery for variola and vaccinia viruses.
    Kennedy R; Poland GA
    Rev Med Virol; 2007; 17(2):93-113. PubMed ID: 17195963
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Experimental discovery of T-cell epitopes: combining the best of classical and contemporary approaches.
    Scharnagl NC; Klade CS
    Expert Rev Vaccines; 2007 Aug; 6(4):605-15. PubMed ID: 17669013
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Virus-epitope vaccine design: informatic matching the HLA-I polymorphism to the virus genome.
    Vider-Shalit T; Raffaeli S; Louzoun Y
    Mol Immunol; 2007 Feb; 44(6):1253-61. PubMed ID: 16930710
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human CD4+ T lymphocytes recognize a vascular endothelial growth factor receptor-2-derived epitope in association with HLA-DR.
    Sun Y; Song M; Jäger E; Schwer C; Stevanovic S; Flindt S; Karbach J; Nguyen XD; Schadendorf D; Cichutek K
    Clin Cancer Res; 2008 Jul; 14(13):4306-15. PubMed ID: 18594014
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A multipeptide vaccine is safe and elicits T-cell responses in participants with advanced stage ovarian cancer.
    Chianese-Bullock KA; Irvin WP; Petroni GR; Murphy C; Smolkin M; Olson WC; Coleman E; Boerner SA; Nail CJ; Neese PY; Yuan A; Hogan KT; Slingluff CL
    J Immunother; 2008 May; 31(4):420-30. PubMed ID: 18391753
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induction of EBV-latent membrane protein 1-specific MHC class II-restricted T-cell responses against natural killer lymphoma cells.
    Kobayashi H; Nagato T; Takahara M; Sato K; Kimura S; Aoki N; Azumi M; Tateno M; Harabuchi Y; Celis E
    Cancer Res; 2008 Feb; 68(3):901-8. PubMed ID: 18245493
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.